BMY News and Press, Bristol-Myers Squibb Company From 04/09/24

2024-04-09 05:49:33 ET Summary After nearly a decade of struggles, Perrigo is poised to turn the corner under the leadership of a new CEO who is only nine months in the seat. Infant formula woes will be resolved in Q2 and comparisons year over year will start to be favorable in th...

2024-04-09 04:21:00 ET If you're building a stream of dividend income to fuel your retirement dreams, it helps to fill your portfolio with businesses that can keep growing through a wide range of economic conditions. Healthcare expenses are generally unavoidable, which makes it a great sect...

2024-04-08 12:00:46 ET More on Bristol-Myers Squibb Company Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis) Bristol Myers Squibb: The Comeback Is Unfolding Bristol-Myers Squibb Is Not A Buy For Me Bristol Myers reports positive ...

2024-04-08 11:38:08 ET More on Bristol-Myers Squibb Company Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis) Bristol Myers Squibb: The Comeback Is Unfolding Bristol-Myers Squibb Is Not A Buy For Me Bristol-Myers highlights safety...

Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program Bristol Myers Squibb (NYSE: BMY) today announced data from the cohorts o...

2024-04-08 07:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Company builds on its strengths to advance patient access, product innovation, culture and inclusion and diversity NORTHAMPTON, MA / ACCESSWIRE / April 8, 2024 / Bristol Myers Squibb Company Bristol Myers Squibb  (NYSE: BMY) today published its 2023 Environmental, Social, and Gov...

2024-04-08 03:22:22 ET Summary The stock market shrugged off rising interest rates and global unrest to produce strong gains during 2023. The DGI for the DIY portfolio also managed double-digit gains for the year. Dividend income grew by 7.9%, lagging the double-digit portfoli...

2024-04-07 13:31:00 ET More on Merck, SPDR S&P Biotech ETF, etc. Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade) Merck: Better Times Ahead On Approvals And Outlook Merck's Future Brightens With Winrevair's Blockbuster Potential ...

2024-04-07 08:00:00 ET More on Phathom Pharmaceuticals Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals ...